SNDX news

Latest 3 stories · newest Nov 2, 2026

SNDX

Syndax Pharmaceuticals appointed Aaron A. Ondrey as Chief Financial Officer, effective November 9, 2026, marking a leadership change.

Leadership Nov 2, 2026 sentiment +0.10 SEC filing ↗

SNDX

Syndax unveils new pipeline assets SNDX-4321 and SNDX-62122

Syndax Pharmaceuticals unveiled two new pipeline assets, a mutant-selective EGFR inhibitor and a next-generation menin inhibitor, and confirmed the Phase 2 trial of axatilimab is on track for data in 4Q26.

Other Jul 14, 2026 sentiment +0.80 SEC filing ↗

SNDX

Syndax Pharmaceuticals offers convertible senior notes due 2031

Syndax Pharmaceuticals is issuing convertible senior notes due 2031 to accredited and institutional investors without SEC registration. The offering allows conversion into cash, common stock, or a combination thereof at the company's election.

Offering Jun 4, 2026 sentiment 0.00 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same SNDX feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/SNDX/newsSTART FREE